T. Rowe Price Associates
TCON

T. Rowe Price Associates’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

T. Rowe Price Associates’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-870
Closed -$113K – 3000
2021
Q2 		$113K Sell
870
-250
-22% -$34.6K ﹤0.01% 2833
2021
Q1 		$184K Buy
1,120
+425
+61% +$81.8K ﹤0.01% 2711
2020
Q4 		$163K Buy
+695
New +$96.7K ﹤0.01% 2581

Other funds holding TCON

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

T. Rowe Price Associates's TCON Position: Q3 2021 in Review

T. Rowe Price Associates sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q3 2021, closing a stake of 870 shares — an estimated $113K sold.

T. Rowe Price Associates first reported a position in TCON in Q4 2020 and held it in 3 quarters. The position peaked at $184K in Q1 2021. 44 funds tracked by Wall St. Rank hold TCON as of Q3 2021.

  • T. Rowe Price Associates reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 870 TRACON Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $113K.
  • T. Rowe Price Associates first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • T. Rowe Price Associates's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $184K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.